Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. The analysis, published in Postgraduate Medicine, highlighted that reSET-O and treatment-as-usual (which includes transmucosal buprenorphine, face-to-face counseling […]
opioids
Pear Therapeutics closes $80M Series D
Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]
7 medical devices combating the opioid crisis
Opioid-related deaths have become an epidemic in the U.S., garnering attention from the White House, the FDA and many other governmental bodies. From 2000 to 2014, nearly half a million Americans died from drug overdoses. In 2015, more than 50,000 people died from drug overdoses, and 33,000 were opioid-related. Prescription overdoses continue to cause more […]
